Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

MTL CEBPA

Next Previous
Drug Profile

MTL CEBPA

Alternative Names: MTL-CEBPA

Latest Information Update: 21 Mar 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator MiNA Therapeutics; University of California at San Francisco; University of Texas Southwestern Medical Center
  • Developer MiNA Therapeutics; National University Hospital (Singapore)
  • Class Antineoplastics; Oligonucleotides; RNA
  • Mechanism of Action RNA interference
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Liver cancer
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase II Liver cancer
  • Phase I/II Mucopolysaccharidosis I
  • Preclinical Acute myeloid leukaemia
  • No development reported Colorectal cancer; Liver disorders; Solid tumours

Most Recent Events

  • 21 Mar 2025 700313282 CTP Push - KDM, HE
  • 21 Mar 2025 Mina Alpha completes a phase-I TIMEPOINT trial in Solid tumours (Combination therapy, Late-stage disease, Second-line therapy or greater) in United Kingdom (IV) (NCT04105335)
  • 25 Jan 2025 Mina Alpha completes a phase-II trials in Liver cancer (Late-stage disease, Combination therapy) in USA, Austria, France, Belgium, Sweden, Netherlands, Singapore (IV) (NCT04710641) (EudraCT2021-005431-23)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top